Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2015 Dec 03





A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536



Minerva Urologica e Nefrologica 2015 Dec 03

language: English

Plasma C1q/tumor necrosis factor-related protein 9; a promising biomarker for diabetic renal vascular injury

Fujita T. 1, Watanabe H. 2, Murata Y. 1, Hemmi S. 1, Yabuki M. 1, Fuke Y. 1, Satomura A. 3, Soma M. 4

1 Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo, Japan;
2 Department of Internal Medicine, Sakuboukai Tokiwadaigeka Hospital, Tokyo, Japan;
3 Department of Laboratory Medicine, Nihon University School of Medicine, Tokyo, Japan;
4 Department of General Medicine, Nihon University School of Medicine, Tokyo, Japan


Adipocytokines are associated with the pathophysiology of type 2 diabetes (T2DM). We analysed the relationship between levels of the plasma C1q/tumor necrosis factor- related protein 9 (CTRP9) and other adipocytokines or the endothelial function in patients with T2DM, and analyzed their trending manner. CTRP9 was detected in plasma from 14 out of a total of 28 patients. The values were not normally distributed. In comparing between groups in which CTRP9 was or was not detected, there were statistically significant differences in the high molecular weight adiponectin (HAN) and the urinary albumin/creatinine ratio (ACR). This indicates that both CTRP9 and HAN reflect the pathophysiology of renal involvement in T2DM. HAN correlated with body mass index, ACR, and homeostasis model assessment of insulin resistance. However, CTRP9 did not correlate with HAN or any other parameters. In conclusion, CTRP9 independently trends in a different manner from HAN, and may reflect diabetic renal vascular risk in association with atherosclerosis and abnormal glucose metabolism besides of impaired vaso-relaxation in patients with T2DM.

top of page

Publication History

Cite this article as

Corresponding author e-mail